CELC Projected Dividend Yield
Celcuity Inc ( NASDAQ : CELC )Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for treatment of multiple solid tumor indications. Co.'s main therapeutic candidate is gedatolisib, a pan-PI3K/mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other approved and investigational therapies that target PI3K or mTOR alone or together. Co.'s therapeutic candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and mammalian target of rapamycin. 20 YEAR PERFORMANCE RESULTS |
|
CELC Dividend History Detail CELC Dividend News CELC Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |
